← All Catalyst Pharmaceuticals, INC filings

Catalyst Pharmaceuticals, INC 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

NASDAQ
CPRX
Catalyst Pharmaceuticals, INC
10-Q: Catalyst Pharma Q3 Earnings Soar on FIRDAPSE, AGAMREE Growth
Catalyst Pharmaceuticals reports strong third-quarter and nine-month financial results, driven by robust sales of FIRDAPSE and AGAMREE, despite generic competition impacting FYCOMPA.
NASDAQ
CPRX
Catalyst Pharmaceuticals, INC
10-Q: Catalyst Pharma Q2 Profit Soars on Strong Drug Sales
Catalyst Pharmaceuticals reports significant revenue and net income growth in Q2 2025, driven by strong performance of FIRDAPSE and AGAMREE, despite anticipated generic competition for FYCOMPA.
NASDAQ
CPRX
Catalyst Pharmaceuticals, INC
10-Q: Catalyst Pharmaceuticals Reports Strong Q1 2025 Results Driven by FIRDAPSE, FYCOMPA, and AGAMREE Sales
Catalyst Pharmaceuticals announces a significant increase in revenue and net income for the first quarter of 2025, driven by strong sales performance across its product portfolio.
NASDAQ
CPRX
Catalyst Pharmaceuticals, INC
10-Q: Catalyst Pharmaceuticals Reports Strong Q3 2024 Results Driven by Product Sales Growth
Catalyst Pharmaceuticals' Q3 2024 results show significant revenue growth and profitability, driven by increased sales of FIRDAPSE, FYCOMPA, and AGAMREE.
NASDAQ
CPRX
Catalyst Pharmaceuticals, INC
10-Q: Catalyst Pharmaceuticals Reports Strong Q2 2024 Results Driven by Product Sales Growth
Catalyst Pharmaceuticals saw a significant increase in revenue and cash reserves in the second quarter of 2024, driven by strong sales of its three key products.
NASDAQ
CPRX
Catalyst Pharmaceuticals, INC
10-Q: Catalyst Pharmaceuticals Reports Q1 2024 Results, Revenue Up 15% Year-Over-Year
Catalyst Pharmaceuticals' first quarter 2024 results show a 15% increase in revenue compared to the same period last year, driven by sales of FIRDAPSE, FYCOMPA and the launch of AGAMREE.